SPOTLIGHT: GSK names Witty as new CEO

After a very long, very public selection process, GlaxoSmithKline has appointed Andrew Witty (photo), now president of the company's European pharma division, to succeed Jean-Pierre Garnier as CEO in May. Analysts said he'd been able to grow sales significantly in Europe despite pricing pressures--an ability that may help him in the U.S. as well. Report

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.